CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus, which is consistent with the WHO recommendation for a “cocktail” therapeutic paradigm; Silevimig Injection provides immediate protection, can be manufactured at scale with standardized processes, and carries no risks of blood-borne infections. Silevimig Injection is the passive immunization product with the smallest dose for rabies, resulting in less injection volume and easier administration, which can effectively reduce patient pain and improve compliance. Silevimig Injection will provide patients with a new option for passive immunization against rabies, and efficiently synergize with the Group’s existing expert network and market resources.   China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”, trade name: 金速希®), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the […]